Price
No data yet.
Social Signal Score
Analyst Ratings
38 analystsRevenue
$10.18M+557.26%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Samarth Kulkarni
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 393
- Beta
- 1.76
- Country
- CH
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 2.51
Financials
Revenue
$10.18M+557.3%Net Income
$-91.15MEBITDA
$-110.52MFree Cash Flow
$-86.62MEPS (diluted)
$-0.94Shares Outstanding (diluted)
96.51M+142.8%Operating Expenses
$80.41MCash & Debt
$2.36BReturn of Capital
$0.00Revenue by Segment (annual)
$3.51MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.51M | $-581.60M | $-6.47 |
| 2024 | $35.00M | $-366.25M | $-4.34 |
| 2023 | $370.00M | $-153.61M | $-1.94 |
| 2022 | $436.0K | $-650.17M | $-8.36 |
| 2021 | $913.08M | $377.66M | $4.97 |
| 2020 | $719.0K | $-348.87M | $-5.29 |
| 2019 | $289.59M | $66.86M | $1.23 |
| 2018 | $3.12M | $-164.98M | $-3.44 |
| 2017 | $41.00M | $-68.36M | $-1.71 |
| 2016 | $5.16M | $-23.20M | $-1.89 |
| 2015 | $247.0K | $-25.83M | $-0.88 |
| 2014 | $0.00 | $-6.80M | $-0.23 |
Valuation
CRSPhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (20)
- Newszacks.com·1d ago·Neutral
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $49.21, signifying a -4.48% move from its prior day's close.
View source ↗ - Newszacks.com·5d ago·Neutral
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know CRISPR Therapeutics AG (CRSP) closed at $51.55 in the latest trading session, marking a -3.45% move from the prior day.
View source ↗ - Newszacks.com·5d ago·Neutral
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
View source ↗ - Newsglobenewswire.com·9d ago·Negative
…ing Data at the American Heart Association (AHA) Scientific Sessions 2026 ZUG, Switzerland and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310®, its investigational CRISPR/Cas9 in vivo gene editing therapy targeting angiopoietin-related protein 3 (ANGPTL3), in patients with severe hypertriglyceridemia will be presented in a late-breaking oral presentation at the American Heart Association (AHA) Scie…
View source ↗ - Newszacks.com·11d ago·Neutral
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $54, representing a -5.82% change from its previous close.
View source ↗ - Newszacks.com·12d ago·Neutral
Wall Street Bulls Look Optimistic About CRISPR Therapeutics (CRSP): Should You Buy? The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
View source ↗ - Newszacks.com·18d ago·Neutral
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
View source ↗ - Newsfool.com·18d ago·Neutral
CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them? CRISPR Therapeutics has two important data readouts coming up soon. In both cases, it'll need to demonstrate that its candidate is more effective than the alternatives in development and on the market.
View source ↗ - Newszacks.com·22d ago·Neutral
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why CRISPR Therapeutics AG (CRSP) reached $54.23 at the closing of the latest trading day, reflecting a -2.64% change compared to its last close.
View source ↗ - Newsseekingalpha.com·23d ago·Neutral
Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing CRISPR Therapeutics AG remains a long-term Buy, anchored by Casgevy's commercial success and management's execution in ex vivo gene editing. Casgevy's Q2 sales grew 78% sequentially, reinforcing its blockbuster potential despite market skepticism and slow initial uptake. Anthropic's AI-driven gene editing discovery introduces potential competitive and funding risks, but clinical impact appears distant.
View source ↗ - News247wallst.com·24d ago·Positive
CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs.
View source ↗ - Newsfool.com·27d ago·Negative
3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026 Even if it's not being officially reported yet, its drug Casgevy is accruing revenue that will show up in earnest beginning next year. That being said, CRISPR Therapeutics' developmental pipeline shows promise well beyond Casgevy's potential.
View source ↗ - Newsfool.com·29d ago·Neutral
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise? CRISPR Therapeutics will likely be a much larger company in 10 years. Much of that time will be spent refining the technologies it already has in hand today.
View source ↗ - Newszacks.com·30d ago·Neutral
Wall Street Analysts Think CRISPR Therapeutics (CRSP) Is a Good Investment: Is It? Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
View source ↗ - Newszacks.com·32d ago·Negative
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know CRISPR Therapeutics AG (CRSP) reached $51.8 at the closing of the latest trading day, reflecting a -2.19% change compared to its last close.
View source ↗ - Newszacks.com·32d ago·Neutral
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
View source ↗ - Newsmarketbeat.com·33d ago·Neutral
CRISPR Therapeutics Eyes CASGEVY Growth, Year-End Pipeline Catalysts CRISPR Therapeutics NASDAQ: CRSP CEO Sam Kulkarni outlined the company's commercial and clinical priorities during a Morgan Stanley discussion, highlighting continued adoption of CASGEVY and expected data updates across several pipeline programs by the end of 2026.
View source ↗ - Newsseekingalpha.com·33d ago·Positive
CRISPR Therapeutics AG (CRSP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript CRISPR Therapeutics AG (CRSP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·42d ago·Neutral
…The Acquisition Case CRISPR Therapeutics transitioned from speculative biotech to commercial stage with FDA approval of CASGEVY, validating its CRISPR/Cas9 platform. CRSP's pipeline targets multi-billion-dollar markets in cardiovascular, autoimmune, oncology, and diabetes, supported by a robust IP portfolio and major pharma partnerships. Current $5.6B market cap and $1.78B net cash position offer acquisition appeal, but most pipeline assets remain early stage and execution risks persist.
View source ↗ - Newszacks.com·45d ago·Neutral
Why Is CRISPR Therapeutics (CRSP) Up 7.1% Since Last Earnings Report? CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?
View source ↗
Earnings
Mon, Nov 9(in 3 weeks)
Consensus estimate $-1.06 per share
Typical surprise -7.6% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 3$-0.94 vs $-1.19beat
- Mon, May 4$-1.28 vs $-1.19miss
- Thu, Feb 12$-1.37 vs $-1.15miss
- Mon, Nov 10$-1.17 vs $-1.26beat
- Tue, Aug 5$-2.40 vs $-1.47miss
- Tue, May 6$-1.58 vs $-1.27miss
Estimates and results for CRSP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CRSP officers and directors.
- Bought
- $50k
- Sold
- $18.4m
1 trade
29 trades
- Kasinger James R.sold
- Kasinger James R.sold
- Behbahani Alisold
- Patel Naimishsold
- Kasinger James R.sold
- Kulkarni Samarthsold
- Prasad Rajusold
- Patel Naimishsold
70 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Thomas Suozzihouse · NY03 · disclosed Oct 5, 2021 (15d later)Sell$50,001 - $100,000
- Thomas Suozzihouse · NY03 · disclosed Sep 23, 2021 (112d later)Buy$50,001 - $100,000
- Marjorie Taylor Greenehouse · GA14 · disclosed Feb 19, 2021 (29d later)Buy$1,001 - $15,000
- James Mountain Inhofesenate · OK · disclosed Jan 15, 2021 (10d later)Sell$1,001 - $15,000
- James Mountain Inhofesenate · OK · disclosed Dec 23, 2020 (1d later)Sell$50,001 - $100,000
- James Mountain Inhofesenate · OK · disclosed Jun 20, 2018 (1d later)Sell$15,001 - $50,000
- James Mountain Inhofesenate · OK · disclosed Nov 8, 2017 (20d later)Buy$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.